A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.

NCT07260513 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor Cancer

Interventions

DRUG: GH2616 Tablets for oral administration at specified doses on scheduled days.

Sponsor

Suzhou Genhouse Bio Co., Ltd.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]